Physician profile
Matthew Henriques
NPI 1023515343
$16,727.63
in general payments reported to CMS, 2019-2025
16 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.78 · 2022: $122 · 2023: $417 · 2024: $1,595 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $13K · Food and Beverage: $3,140 · Education: $203 · Travel and Lodging: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $13,124.00 |
| Food and Beverage | $3,139.95 |
| Education | $202.50 |
| Travel and Lodging | $123.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,279.60 | 2024-2025 | Assurity, Tacticath, Aveir |
| Medtronic, INC. | $4,792.06 | 2023-2025 | Micra, Linq II |
| Boston Scientific Corporation | $4,188.86 | 2025 | Emblem Mri S-Icd, Accolade Sr |
| Biotronik INC. | $666.37 | 2024-2025 | |
| Pfizer INC. | $166.83 | 2021-2024 | |
| Biosense Webster, INC. | $133.25 | 2024-2025 | Carto 3, Nuvision Ice Catheter |
| Amgen INC. | $133.09 | 2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.21 | 2022 | |
| Cardiva Medical, INC. | $70.82 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| E.R. Squibb & Sons, L.L.C. | $31.45 | 2023 | Camzyos |
| Esperion Therapeutics, INC. | $29.87 | 2023 | Nexletol |
| Alnylam Pharmaceuticals INC. | $28.51 | 2023 | Amvuttra |
| Philips North America LLC | $28.13 | 2025 | Igt Devices Undivided |
| Astrazeneca Pharmaceuticals LP | $21.75 | 2023 | Farxiga |
| Heartflow, INC. | $18.83 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $16.00 | 2023 | Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Henriques listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.